ChromaDex Adds New AnthOrigin™ to Its Proprietary Ingredient Portfolio
October 03 2016 - 5:30AM
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health,
wellness and nutritional ingredients that creates science-based
solutions to dietary supplement, food and beverage, skin care,
sports nutrition, and pharmaceutical products, announced today that
it has added its new AnthOrigin™ naturally extracted anthocyanins
(≥15%) product to its portfolio of industry-leading health and
wellness ingredients.
The Company entered into an exclusive worldwide
license and supply agreement for patent-pending
Suntava® Purple Corn back in May, 2015. The
variety of Suntava® purple corn grown for AnthOrigin™
maintains more of its rich, purple anthocyanins in the husk versus
in the kernel than traditional varieties.
Implied by its name, AnthOrigin™ delivers
high-content anthocyanins and other healthy polyphenols, from US
origin, non-gmo purple corn husk that has been extracted using a
proprietary, solvent-free, water extraction
technology. AnthOrigin™ will be a perfect choice for those
looking for natural, clean label ways to innovate in the areas of
weight management, support for healthy blood sugar levels already
within the normal range, heart health, anti-aging and eye health.
Over 50% of AnthOrigin™ anthocyanins are cyanidin 3-glucoside (C3G)
– one of the most clinically studied of the anthocyanins.
Commenting on the launch, Frank Jaksch, CEO and
co-founder of ChromaDex stated, "AnthOrigin™ is a game changer for
anthocyanins. It comes from a unique antioxidant-rich source
that is grown and processed in North America, so manufacturers and
consumers can feel good about it. It also helps protect our
customers from the supply and price volatility frequently
associated with other sources. It’s a great addition to our growing
portfolio of proprietary ingredients.”
About ChromaDex:ChromaDex
leverages its complementary business units to discover, acquire,
develop and commercialize patented and proprietary ingredient
technologies that address the dietary supplement, food, beverage,
skin care and pharmaceutical markets. In addition to our ingredient
technologies unit, we also have business units focused on natural
product fine chemicals (known as "phytochemicals"), chemistry and
analytical testing services, and product regulatory and safety
consulting (known as Spherix Consulting). As a result of our
relationships with leading universities and research institutions,
we are able to discover and license early stage, IP-backed
ingredient technologies. We then utilize our in-house chemistry,
regulatory and safety consulting business units to develop
commercially viable ingredients. Our ingredient portfolio is backed
with clinical and scientific research, as well as extensive IP
protection. Our portfolio of patented ingredient technologies
includes NIAGEN® nicotinamide riboside; pTeroPure® pterostilbene;
PURENERGY®, a caffeine-pTeroPure® co-crystal; IMMULINA™, a
spirulina extract; and AnthOrigin™, anthocyanins derived from a
domestically-produced, water-extracted purple corn husk. To learn
more about ChromaDex, please visit www.ChromaDex.com.
Forward-Looking Statements:This
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to potential for AnthOrigin™
and related claims. Statements that are not a description of
historical facts constitute forward-looking statements and may
often, but not always, be identified by the use of such words as
"expects", "anticipates", "intends", "estimates", "plans",
"potential", "possible", "probable", "believes", "seeks", "may",
"will", "should", "could" or the negative of such terms or other
similar expressions. More detailed information about ChromaDex and
the risk factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended January 2, 2016, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
ChromaDex Public Relations Contact:
Breah Ostendorf, Director of Marketing
949-537-4103
breaho@chromadex.com
ChromaDex Investor Relations Contact:
Andrew Johnson, Director of Investor Relations
949-419-0288
andrewj@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2024 to May 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From May 2023 to May 2024